Gregory Critchfield | GenomeWeb

Gregory Critchfield

Jul 13, 2015

Epic Sciences has appointed Sera Prognostics President and CEO Gregory Critchfield to its board. He has more than 30 years of experience in the clinical pathology and diagnostics space and was the former president of Myriad Genetics. Prior to that, Critchfield was chief medical and science officer for Quest Diagnostics. He currently is also on the boards of Integrated Diagnostics, Nodality, and Metamark Genetics.

More Like This

Feb 21, 2017

Raymond Stevens

Raymond Stevens has been appointed to Danaher's board of directors. Stevens currently serves as provost professor of biological sciences and chemistry and director of the Bridge Institute at the University of Southern California. Before that, he was a professor of molecular biology and chemistry at the Scripps Research Institute. 

Feb 20, 2017

John Thompson

Illumina has named John Thompson to its board of directors, effective May 3. Thompson is chairman of the board at Microsoft. He has also served as CEO at Symantec and Virtual Instruments, has held various roles over 28 years at IBM, and has served on the boards of Symantec, Northern Indiana Public Service Company, Fortune Brands, Seagate Technologies, and UPS. He is a member of the board of trustees for the Wetlands America Trust and was formerly a member of the national board of Teach for America. In addition, he has served on several government commissions, including the Financial Crisis Inquiry Commission, the National Infrastructure Advisory Council, and the Silicon Valley Blue Ribbon Task Force on Aviation Security and Technology. 

Feb 17, 2017

Igor Gitelman

Cancer Genetics has appointed Igor Gitelman the firm's principal accounting officer, replacing Victor Cross who had been promoted to that position in early January. The company said Cross left for family reasons. From late 2005 to late 2016 Gitelman was assistant vice president of finance and tax at BioReference Laboratories. 

Feb 17, 2017

Michael Terry

Biocept has appointed Michael Terry to the newly created position of senior vice president of commercial operations, where he will lead the company's commercial organization and oversee its business development initiatives. Prior to joining Biocept, Terry served as executive vice president of commercial operations and corporate development at liquid biopsy firm Trovagene. He has also served as executive vice president of Sequenom as CEO of neonatal diagnostics startup Ligand Dx, and has worked for Lumenis, GE Healthcare, and Aspect Medical Systems, among others.

Feb 17, 2017

Frederick Eibel

MolecularMD has appointed Frederick Eibel as senior vice president and chief marketing officer. Eibel joins MolecularMD from Wren Laboratories, where he served as senior vice president. Before his time at Wren, Eibel spent 23 years at Roche Diagnostics in various roles. He has also held leadership roles at Rain Dance Technologies, Sequenom, Life Technologies, and Gen Probe.

Feb 17, 2017

George Davis

Perthera has appointed George Davis to its board of directors. Davis currently serves as CEO of Gemstone Biotherapeutics. Previously, he served as president and vice chairman of Aether Systems. He has also served as CEO and director of Avatech Solutions.

Feb 16, 2017

Leeona Galligan

Almac Diagnostics has appointed Leeona Galligan as VP of UK Operations. She will be responsible for all UK-based operations, including commercial biomarker discovery, CLIA/FDA compliant analytical validation, downstream clinical testing, manufacturing and shipping of clinical specimens, and release of controls and reagents for registrational clinical trials. Galligan joined Almac in September 2009 as a senior scientist. She was appointed clinical testing laboratory manager in 2012 and was subsequently promoted to head of UK lab-based operations.

Feb 14, 2017

David Agus

David Agus has joined personalized oncology firm Tempus as Chairman of the firm's scientific advisory board. He is currently a Professor at the University of Southern California and head of its Ellison Institute for Transformative Medicine. Agus holds a medical degree from the University of Pennsylvania and completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center.

Feb 10, 2017

Amy Sturm

Geisinger's Genomic Medicine Institute has appointed Amy Sturm as director of cardiovascular genomic counseling. Sturm also serves as a member of the ClinGen Cardiovascular Clinical Domain Working Group. She joins Geisinger from Ohio State University, where she served as associate professor in the Division of Human Genetics at OSU's Wexner Medical Center. She has served on the board of directors of the National Society of Genetic Counselors, and works extensively with the Familial Hypercholesterolemia Foundation and the Sudden Arrhythmia Death Syndromes Foundation.

Feb 09, 2017

Yaniv Erlich

MyHeritage has appointed Yaniv Erlich as chief science officer. He will lead the company's scientific development and strategy for its MyHeritage DNA service. Erlich comes to MyHeritage from Columbia University, where he served as assistant professor of computer science and computational biology. He has also served as a core member of the New York Genome Center, the principal investigator and Whitehead Fellow at MIT's Whitehead Institute, founder of DNA.LAND, and the principal investigator of the Erlich DNA lab.

Feb 09, 2017

Bradford Crutchfield

10x Genomics has appointed Bradford Crutchfield to the position of chief commercial officer, replacing John Pouk, who had been serving as the company's interim CCO. Pouk will stay on as senior vice president of commercial operations. Crutchfield previously served as senior vice president of Qiagen's life sciences business. He has also served as vice president and general manager of Illumina's Europe, Middle East, and Africa operations, as director of NanoString Technologies, and in various roles at Bio-Rad Laboratories. 

Feb 09, 2017

Richard Dennis

Proteome Sciences said this week that it has appointed Richard Dennis as the company's first chief commercial officer, effective beginning in April. Dennis most recently served as director of international sales at Quanterix. He also previously served as vice president of international commercial operations at Bioscale, and director of sales at Meso Scale Discovery.

Feb 08, 2017

Gary Riordan

HealthTell has appointed Gary Riordan as VP of regulatory and quality. Riordan has previously held positions at various companies in the diagnostic industry, including NanoString, Accumetrics, Sequenom, PrimeraDx, and Roche Molecular Systems. He began his career at the US Food and Drug Administration, where he spent six years at the Center for Biologics Evaluation and Research as a reviewer for in vitro diagnostic tests for HIV and Hepatitis.

Feb 08, 2017

Birgit Funke

Veritas Genetics has appointed Birgit Funke as VP of clinical affairs. Funke is a board-certified molecular geneticist and serves as an associate professor of pathology at Harvard Medical School. In addition to her new appointment with Veritas, she will continue her work at Partners Healthcare's Laboratory of Molecular Medicine. Funke also serves as co-chair of ClinGen's Cardiovascular Domain Working Group, as chair of the genetics subdivision of the Association for Molecular Pathology, as advisor on next-generation sequencing for the US Food and Drug Administration, and as a member of the College of American Pathologists' Next-Generation Sequencing Project Team.

Feb 08, 2017

Candia Brown

Swift Biosciences has appointed Candia Brown as VP of global marketing. Brown joins Swift from Fluidigm where she served as director of single-cell genomics. Prior to Fluidigm, she directed strategic marketing for DNA applications within Affymetrix, and held various position at Applied Biosystems. Brown also conducted research at Applied Biosystems, the Baxter Corporation (MicroScan Division), and the Biocircuits Corporation.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.